Ramin Tolouian
1*, German T Hernandez
11 Division of Nephrology & Hypertension, Department of Internal Medicine, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center, El Paso, TX, USA.
*Corresponding Author: *Corresponding author: Dr. Ramin Tolouian, Division of Nephrology & Hypertension, Department of Internal Medicine, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center, El Paso, TX 79905, USA. Tel: +915-545 6618, Fax: +915-545 6634, Email:
ramin.tolouian@ttuhsc.edu
Implication for health policy/practice/research/medical education:
The ability to identify diabetic patients at high risk for progressive renal decline should be one of the priorities of nephrology community. Early identification may lead to improved clinical management, quality of life, and a decrease in the already high burden of morbidity. An ideal biomarker should be relatively inexpensive and readily measured either in serum or urine.
Please cite this paper as: Tolouian R, Hernandez GT. Prediction of Diabetic Nephropathy: The need for a sweet biomarker. J Nephropathology. 2013; 2(1): 4-5. DOI: 10.5812/nephropathol.8966